Biology:RAD51C
Generic protein structure example |
RAD51 homolog C (S. cerevisiae), also known as RAD51C, is a protein which in humans is encoded by the RAD51C gene.[1][2]
Function
The RAD51C protein is one of five paralogs of RAD51, including RAD51B (RAD51L1), RAD51C (RAD51L2), RAD51D (RAD51L3), XRCC2 and XRCC3. They each share about 25% amino acid sequence identity with RAD51 and each other.[3]
The RAD51 paralogs are all required for efficient DNA double-strand break repair by homologous recombination and depletion of any paralog results in significant decreases in homologous recombination frequency.[4]
RAD51C forms two distinct complexes with other related paralogs: BCDX2 (RAD51B-RAD51C-RAD51D-XRCC2) and CX3 (RAD51C-XRCC3). These two complexes act at two different stages of homologous recombinational DNA repair. The BCDX2 complex is responsible for RAD51 recruitment or stabilization at damage sites.[4] The BCDX2 complex appears to act by facilitating the assembly or stability of the RAD51 nucleoprotein filament.
The CX3 complex acts downstream of RAD51 recruitment to damage sites.[4] The CX3 complex was shown to associate with Holliday junction resolvase activity, probably in a role of stabilizing gene conversion tracts.[4]
The RAD51C gene is one of genes four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors.[5] Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing has been observed for this gene and two variants encoding different isoforms have been identified.[1]
Clinical significance
A characteristic of many cancer cells is that parts of some genes contained within these cells have been recombined with other genes. One such gene fusion that has been identified in a MCF-7 breast cancer cell line is a chimera between the RAD51C and ATXN7 genes.[6][7] Since the RAD51C protein is involved in repairing double strand chromosome breaks, this chromosomal rearrangement could be responsible for the other rearrangements.[7]
Mutation, splicing, and epigenetic deficiency in cancer
RAD51C mutation increases the risk for breast and ovarian cancer, and was first established as a human cancer susceptibility gene in 2010.[8][9][10] Carriers of an RAD51C mutation had a 5.2-fold increased risk of ovarian cancer, indicating that RAD51C is a moderate ovarian cancer susceptibility gene.[11] A pathogenic mutation of RAD51C was present in approximately 1% to 3% of unselected ovarian cancers, and among mutation carriers, the lifetime risk of ovarian cancer was approximately 10-15%.[12][13][14][15]
In addition, there are three other causes of RAD51C deficiency that also appear to increase cancer risk. These are alternative splicing, promoter methylation and repression by over-expression of EZH2.
Three alternatively spliced RAD51C transcripts were identified in colorectal cancers. Variant 1 is joined from the 3' end of exon-6 to the 5' end of exon-8, variant 2 is joined at the 3' end of exon-5 to the 5' end of exon-8, and variant 3 is joined from the 3' end of exon-6 to the 5' end of exon-9.[16] Presence and mRNA expression of variant 1 RAD51C was found in 47% of colorectal cancers. Variant 1 mRNA was expressed about 5-fold more frequently in colorectal tumors than in non-tumor tissues, and when present, was expressed 8-fold more frequently than wild-type RAD51C mRNA. The authors concluded that variant 1 mRNA was associated with the malignant phenotype of colorectal cancers[16]
In the case of gastric cancer, reduced expression of RAD51C was found in about 40% to 50% of tumors, and almost all tumors with reduced RAD51C expression had methylation of the RAD51C promoter.[17] On the other hand, methylation of the RAD51C promoter was only found in about 1.5% of ovarian cancer cases.[13]
EZH2 protein is up-regulated in numerous cancers.[18][19] EZH2 mRNA is up-regulated, on average, 7.5-fold in breast cancer, and between 40% to 75% of breast cancers have over-expressed EZH2 protein.[20] EZH2 is the catalytic subunit of Polycomb Repressor Complex 2 (PRC2) which catalyzes methylation of histone H3 at lysine 27 (H3K27me) and mediates epigenetic gene silencing of target genes via local chromatin reorganization.[19] EZH2 targets RAD51C, reducing RAD51C mRNA and protein expression (and also represses other RAD51 paralogs RAD51B, RAD51D, XRCC2 and XRCC3).[21] Increased expression of EZH2, leading to repression of RAD51 paralogs and consequent reduced homologous recombinational repair, was proposed as a cause of breast cancer.[22]
Interactions
RAD51C has been shown to interact with:
References
- ↑ 1.0 1.1 "Entrez Gene: RAD51C RAD51 homolog C (S. cerevisiae)". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=5889.
- ↑ "Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes". Nucleic Acids Research 26 (5): 1179–84. March 1998. doi:10.1093/nar/26.5.1179. PMID 9469824.
- ↑ "Domain mapping of the Rad51 paralog protein complexes". Nucleic Acids Research 32 (1): 169–78. 2004. doi:10.1093/nar/gkg925. PMID 14704354.
- ↑ 4.0 4.1 4.2 4.3 "Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway". Molecular and Cellular Biology 33 (2): 387–95. January 2013. doi:10.1128/MCB.00465-12. PMID 23149936.
- ↑ "17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes". Cancer Research 60 (19): 5371–5. October 2000. PMID 11034073.
- ↑ Wade N (2008-12-25). "The Chaos Inside a Cancer Cell". Science Visuals. NYTimes.com. https://www.nytimes.com/2008/12/25/science/25visual.html.
- ↑ 7.0 7.1 "A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome". Genome Research 19 (2): 167–77. February 2009. doi:10.1101/gr.080259.108. PMID 19056696.
- ↑ "Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene". Nature Genetics 42 (5): 410–4. May 2010. doi:10.1038/ng.569. PMID 20400964.
- ↑ "RAD51C germline mutations in breast and ovarian cancer cases from high-risk families". PLOS ONE 6 (9): e25632. 2011. doi:10.1371/journal.pone.0025632. PMID 21980511. Bibcode: 2011PLoSO...625632C.
- ↑ "Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer". Breast Cancer Research and Treatment 155 (2): 215–22. January 2016. doi:10.1007/s10549-015-3674-y. PMID 26740214.
- ↑ "Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population". Journal of Clinical Oncology 33 (26): 2901–7. September 2015. doi:10.1200/JCO.2015.61.2408. PMID 26261251.
- ↑ "Genetic testing for RAD51C mutations: in the clinic and community". Clinical Genetics 88 (4): 303–12. October 2015. doi:10.1111/cge.12548. PMID 25470109.
- ↑ 13.0 13.1 "Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status". Scientific Reports 4: 4026. February 2014. doi:10.1038/srep04026. PMID 24504028. Bibcode: 2014NatSR...4E4026C.
- ↑ "Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas". Clinical Cancer Research 20 (3): 764–75. February 2014. doi:10.1158/1078-0432.CCR-13-2287. PMID 24240112.
- ↑ "Current and future role of genetic screening in gynecologic malignancies". American Journal of Obstetrics and Gynecology 217 (5): 512–521. November 2017. doi:10.1016/j.ajog.2017.04.011. PMID 28411145.
- ↑ 16.0 16.1 "Overexpression of Rad51C splice variants in colorectal tumors". Oncotarget 6 (11): 8777–87. April 2015. doi:10.18632/oncotarget.3209. PMID 25669972.
- ↑ "RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib". Molecular Cancer Therapeutics 12 (6): 865–77. June 2013. doi:10.1158/1535-7163.MCT-12-0950. PMID 23512992.
- ↑ "The role of EZH2 in tumour progression". British Journal of Cancer 106 (2): 243–7. January 2012. doi:10.1038/bjc.2011.551. PMID 22187039.
- ↑ 19.0 19.1 "Diverse involvement of EZH2 in cancer epigenetics". American Journal of Translational Research 7 (2): 175–93. 2015. PMID 25901190.
- ↑ "EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells". Proceedings of the National Academy of Sciences of the United States of America 100 (20): 11606–11. September 2003. doi:10.1073/pnas.1933744100. PMID 14500907. Bibcode: 2003PNAS..10011606K.
- ↑ "The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells". Neoplasia 7 (11): 1011–9. November 2005. doi:10.1593/neo.05472. PMID 16331887.
- ↑ "The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer". Journal of Molecular Histology 37 (5–7): 219–23. September 2006. doi:10.1007/s10735-006-9042-9. PMID 16855786.
- ↑ 23.0 23.1 "Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways". Human Molecular Genetics 13 (12): 1241–8. June 2004. doi:10.1093/hmg/ddh135. PMID 15115758.
- ↑ 24.0 24.1 24.2 24.3 "RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51". The Journal of Biological Chemistry 277 (10): 8406–11. March 2002. doi:10.1074/jbc.M108306200. PMID 11744692.
- ↑ "Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange". Genes & Development 15 (24): 3308–18. December 2001. doi:10.1101/gad.935501. PMID 11751636.
- ↑ 26.0 26.1 26.2 "Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells". Nucleic Acids Research 30 (4): 1009–15. February 2002. doi:10.1093/nar/30.4.1009. PMID 11842113.
- ↑ "Homologous-pairing activity of the human DNA-repair proteins Xrcc3.Rad51C". Proceedings of the National Academy of Sciences of the United States of America 98 (10): 5538–43. May 2001. doi:10.1073/pnas.091603098. PMID 11331762.
Further reading
- "Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes". Nucleic Acids Research 26 (5): 1179–84. March 1998. doi:10.1093/nar/26.5.1179. PMID 9469824.
- "Evidence for simultaneous protein interactions between human Rad51 paralogs". The Journal of Biological Chemistry 275 (22): 16443–9. June 2000. doi:10.1074/jbc.M001473200. PMID 10749867.
- "Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism". Nature Genetics 25 (3): 298–301. July 2000. doi:10.1038/77053. PMID 10888877.
- "Multiple genes at 17q23 undergo amplification and overexpression in breast cancer". Cancer Research 60 (19): 5340–4. October 2000. PMID 11034067.
- "17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes". Cancer Research 60 (19): 5371–5. October 2000. PMID 11034073.
- "Homologous-pairing activity of the human DNA-repair proteins Xrcc3.Rad51C". Proceedings of the National Academy of Sciences of the United States of America 98 (10): 5538–43. May 2001. doi:10.1073/pnas.091603098. PMID 11331762.
- "Sequence, chromosomal location and expression analysis of the murine homologue of human RAD51L2/RAD51C". Gene 271 (1): 59–67. June 2001. doi:10.1016/S0378-1119(01)00498-X. PMID 11410366. https://zenodo.org/record/1260049.
- "Complex formation by the human RAD51C and XRCC3 recombination repair proteins". Proceedings of the National Academy of Sciences of the United States of America 98 (15): 8440–6. July 2001. doi:10.1073/pnas.111005698. PMID 11459987. Bibcode: 2001PNAS...98.8440M.
- "RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51". The Journal of Biological Chemistry 277 (10): 8406–11. March 2002. doi:10.1074/jbc.M108306200. PMID 11744692.
- "Identification and purification of two distinct complexes containing the five RAD51 paralogs". Genes & Development 15 (24): 3296–307. December 2001. doi:10.1101/gad.947001. PMID 11751635.
- "Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange". Genes & Development 15 (24): 3308–18. December 2001. doi:10.1101/gad.935501. PMID 11751636.
- "Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells". Nucleic Acids Research 30 (4): 1001–8. February 2002. doi:10.1093/nar/30.4.1001. PMID 11842112.
- "Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells". Nucleic Acids Research 30 (4): 1009–15. February 2002. doi:10.1093/nar/30.4.1009. PMID 11842113.
- "Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1". Oncogene 21 (32): 5002–5. July 2002. doi:10.1038/sj.onc.1205656. PMID 12118380.
- "Complex formation by the human Rad51B and Rad51C DNA repair proteins and their activities in vitro". The Journal of Biological Chemistry 278 (4): 2469–78. January 2003. doi:10.1074/jbc.M211038200. PMID 12427746.
- "Identification of functional domains in the RAD51L2 (RAD51C) protein and its requirement for gene conversion". The Journal of Biological Chemistry 278 (46): 45445–50. November 2003. doi:10.1074/jbc.M308621200. PMID 12966089.
- "Functional interaction between the Bloom's syndrome helicase and the RAD51 paralog, RAD51L3 (RAD51D)". The Journal of Biological Chemistry 278 (48): 48357–66. November 2003. doi:10.1074/jbc.M308838200. PMID 12975363.
- "Domain mapping of the Rad51 paralog protein complexes". Nucleic Acids Research 32 (1): 169–78. 2004. doi:10.1093/nar/gkg925. PMID 14704354.
- "RAD51C is required for Holliday junction processing in mammalian cells". Science 303 (5655): 243–6. January 2004. doi:10.1126/science.1093037. PMID 14716019. Bibcode: 2004Sci...303..243L.